Pharmahungary Group – Remembrane Srl Press Release
Pharmahungary Group and Remembrane developed and validated a medium throughput in vitro screening platform for testing potential cardiocytoprotective drug candidates against ischemia/reperfusion injury in the presence of hypercholesterolemia/metabolic disease comorbidities.
The screening platform has been recently described in Frontiers in Physiology (Makkos et al., Front. Physiol. 2020; 10:1564.